povetacicept   Click here for help

GtoPdb Ligand ID: 14426

Synonyms: ALPN-303 | TACI vTD-Fc
Immunopharmacology Ligand
Compound class: Peptide
Comment: Povetacicept (ALPN-303) is a Fc fusion protein that contains a variant TACI domain of the TNFRSF13B receptor for the peptide cytokines B cell activating factor (BAFF; TNFSF13B) and a proliferation-inducing ligand (APRIL; TNFSF13) [3]. It functionally antagonises the cellular signalling pathways of these ligands via TNFRSF13B on B cells.
In the peptide sequence provided the TACI domain is amino acids 1-43, with a short linker (GSGGGGS 44-50 ) and the remainder being the Fc domain. The functional peptide is a dimer, linked by inter-chain disulphide bridges.
References
1. Barratt J, Zhang H, Han SH, Suzuki Y, Tumlin J, Chacko B, Noronha IL, Madan A, Duivenvoorden R, Azzi JR et al.. (2026)
Interim Analysis of a Phase 3 Trial of Povetacicept in IgA Nephropathy.
N Engl J Med, [Epub ahead of print]. [PMID:42912669]
2. Davies R, Peng SL, Lickliter J, McLendon K, Enstrom A, Chunyk AG, Blanchfield L, Wang N, Blair T, Thomas HM et al.. (2024)
A first-in-human, randomized study of the safety, pharmacokinetics and pharmacodynamics of povetacicept, an enhanced dual BAFF/APRIL antagonist, in healthy adults.
Clin Transl Sci, 17 (11): e70055. [PMID:39494621]
3. Evans LS, Lewis KE, DeMonte D, Bhandari JG, Garrett LB, Kuijper JL, Ardourel D, Wolfson MF, Debrot S, Mudri S et al.. (2023)
Povetacicept, an Enhanced Dual APRIL/BAFF Antagonist That Modulates B Lymphocytes and Pathogenic Autoantibodies for the Treatment of Lupus and Other B Cell-Related Autoimmune Diseases.
Arthritis Rheumatol, 75 (7): 1187-1202. [PMID:36705554]
4. FDA. 
Orphan Drug Designations and Approvals: povetacicept, membranous nephropathy.
Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1115725
5. FDA. 
Orphan Drug Designations and Approvals: povetacicept, myasthenia gravis.
Accessed on 29/04/2026. Modified on 29/04/2026. www.accessdata.fda.gov/, www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1121025
6. Rinaldi E, Puleo E, Consonni A, Miglietti M, Mantegazza R, Wang N, Peng SL, Lewis KE, Dillon SR, Baggi F. (2025)
Povetacicept (ALPN-303; TACI vTD-Fc), an enhanced, potent dual inhibitor of BAFF and APRIL, ameliorates experimental autoimmune myasthenia gravis in C57BL/6N mice.
Front Immunol, 16: 1533093. [PMID:40547042]
7. Sharma I, Panta R. (2025)
Emerging Therapies in IgA Nephropathy: From A Proliferation-Inducing Ligand (APRIL) and B-cell Activating Factor (BAFF) Inhibitors to Precision Medicine.
Cureus, 17 (12): e99870. [PMID:41573494]